First-Line Metformin Use for DM Up; Sulfonylurea Use Down

Among patients with type 2 diabetes initiating antidiabetes drugs (ADDs), first-line use of metformin has increased since 2005, while sulfonylureas have remained the most popular second-line agent, research in Diabetes Care suggests. Researchers identified patients with type 2 diabetes who initiated any ADD and patients who initiated second-line ADD after first-line metformin. They found that between 2005 and 2016, first-line use of metformin increased from 60 to 77%, while first-line use of sulfonylureas decreased from 20% to 8%.

Fri, 17 Nov 2017 BREAKING NEWS
FDA OKs Drug for Hemophilia A With Factor VIII Inhibitors

Hemlibra (emicizumab-kxwh) has been approved by the FDA to prevent or reduce the frequency of bleeding episodes among hemophilia A patients with Factor VIII inhibitors. The subcutaneously administered medication was approved to treat both adult and pediatric patients. The FDA granted Priority Review and Breakthrough Therapy designations, and Hemlibra has received Orphan Drug designation. Common adverse events include injection site reaction, headache, and arthralgia. Hemlibra is produced by Genentech, based in South San Francisco.

Fri, 17 Nov 2017 BREAKING NEWS
FDA Investigation Linked to Drop in Codeine Rx for Children

The FDA investigation into the safety of codeine use by children, which culminated in a black box warning in February 2013, led to substantially decreased codeine prescribing to children after tonsillectomy and/or adenoidectomy, according to a study published in Pediatrics. The researchers found that the FDA investigation was associated with a significant −13.3 percentage point level change in the proportion of children with at least one prescription fill for codeine after tonsillectomy and/or adenoidectomy.

Fri, 17 Nov 2017 BREAKING NEWS
Drug Combo Doesn’t Lengthen Glioblastoma Survival

In patients with progressive glioblastoma, treatment with lomustine plus bevacizumab doesn't confer a survival advantage over treatment with lomustine alone, research in the New England Journal of Medicine finds. Researchers randomly assigned patients with progression after chemoradiation to receive lomustine plus bevacizumab or lomustine alone and found that median overall survival was 9.1 months in the combination group and 8.6 months in the monotherapy group. But locally assessed progression-free survival was 2.7 months longer in the combination group than the monotherapy group.

Fri, 17 Nov 2017 BREAKING NEWS
AHA: Supervised Exercise Ups 6-Minute Walking Distance in PAD

But no improvement seen with branulocyte-macrophage colony stimulating factor Supervised treadmill exercise, but not granulocyte-macrophage colony-stimulating factor (GM-CSF), improves six-minute walking distance among patients with peripheral artery disease (PAD), according to a study published online Nov. 15 in the Journal of the American Medical Association to coincide with the American Heart Association’s Scientific Sessions, held … Continue reading AHA: Supervised Exercise Ups 6-Minute Walking Distance in PAD

Fri, 17 Nov 2017 BREAKING NEWS
FDA Approves Drug With Digital Ingestion Tracking System

The first drug in the U.S. with a digital ingestion tracking system has been approved by the FDA. Abilify MyCite consists of aripiprazole tablets with an embedded sensor in each that sends a message to a wearable patch when the medication been taken. This allows the patients to track medication ingestion via smartphone, and they can also permit their physicians and caregivers to access the information through a web-based portal.

Thu, 16 Nov 2017 BREAKING NEWS